Download Free Medical Infections Following Renal Transplantation and An Update on CMV PowerPoint Presentation

Infections Following Renal Transplantation and An Update on CMV PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Infections Following Renal Transplantation and An Update on CMV" by K.Vinay Ranga MD, MRCP (UK).

This medical PowerPoint presentation talks about infections as a common complication following renal transplantation, and they can occur at any time after the surgery. Patients who have undergone renal transplantation are at an increased risk of infections due to immunosuppressive medications that are necessary to prevent rejection of the transplanted kidney.

Some of the most common infections following renal transplantation include Urinary tract infections, Cytomegalovirus (CMV) infection, Epstein-Barr virus (EBV) infection, and Bacterial infections.

Preventing infections after renal transplantation is essential for the success of the procedure. Patients are typically prescribed prophylactic antibiotics and antiviral medications to prevent infections. It is also important for patients to maintain good hygiene, avoid contact with sick individuals, and follow their immunosuppressive medication regimen as prescribed by their healthcare provider.

Tags : Renal Transplantation, immunosuppressive medications, Urinary tract infections, Cytomegalovirus (CMV) infection, Epstein-Barr virus (EBV) infection, Bacterial infections, Dermatology, Dermatology PowerPoint presentation

Published on : Mar 31, 2023 | Views : 1386 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Infections Following Renal Transplantation and An Update on CMV K.Vinay Ranga MD, MRCP (UK) Associate Professor Internal Medicine / Nephrology UTHSC
Slide 2-

ppt slide no 2 content not found
Slide 3-

INFECTION IN IMMUNOSUPPRESSED PATIENTS: BASIC PRINCIPLES Inflammatory response attenuated by immunosuppression. may abolish typical signs/symptoms decreased sensitivity of serological, radiological tests Effects of established infection may be devastating. Treatment may have more toxicities ! Rifampin - decrease CNI Erythromycin, azoles increase CNI Synergistic nephrotoxicity - aminoglycosides, Amphotericin B, high dose Co-trimoxazole
Slide 4-

Infections in Transplant Recipients Net state of immunosuppression Epidemiological exposure
Slide 5-

KNOWN PATHOGEN More potent immunosuppression Widespread prophylaxis Modified presentation Symptoms Timing Spectrum Drug resistance
Slide 6-

The Net State of Immune Deficiency Immunosuppression (current and past) Prior therapies-chemotherapy, Antibiotics Muco-cutaneous barrier integrity (catheters, lines, drains) Neutropenia, lymphopenia Underlying immune deficiencies (e.g. hypogammaglobulinemia, SLE) Metabolic: uremia, malnutrition, DM, cirrhosis Viral co-infection (e.g. CMV, HCV, HBV) Risk assessment in transplantation
Slide 7-

Greater infectious risk Induction therapy–lymphocyte depletion High-dose steroids Plasmapheresis High rejection risk Early graft rejection Graft dysfunction Active/latent D/R infection Technical complications Anastomotic leak Bleeding Wound infection/poor wound healing Prolonged intubation/ ICU care Surgical, vascular or urinary catheters
Slide 8-

Lower infectious risk Good HLA match Technically successful surgery Good graft function Appropriate surgical prophylaxis Effective antiviral prophylaxis PCP prophylaxis Appropriate vaccination AJT. Fishman JA.Volume 9, Supp. S4, pages S3–S6, December 2009
Slide 9-

Epidemiological Exposure Donor derived infections Recipient derived infections Community aquired infections Nosocomial infections
Slide 10-

EPIDEMIOLOGICAL EXPOSURES Overlapping but distinct exposures Community – CAP, CA-MRSA, Endemic mycosis, respiratory viruses, enteric viruses Nosocomial – MRSA, Aspergillus, MDR gram negatives, VRE Donor – latent or active infection Recipient – latent or active infection
Slide 11-

DONOR DERIVED INFECTION BACTERIAL Gram positive Gram negative Mycobacterial Spirochetes FUNGAL Candida Cryptocococcus Coccidioides Histoplasma Aspergillus PARASITIC Malaria Chagas disease Strongyloides Schistosomiasis Flukes VIRAL Hepatitis A, B, C, D… HIV HHV 1 - 8 Rabies West Nile Virus LCMV PRION vCJD PATHOGENS
Slide 12-

HOW DO YOU RECOGNIZE UNUSUAL DONOR TRANSMITTED INFECTION? These infections often (but not always) occur early post-transplant They are often clinically very aggressive and may be difficult to diagnose Rare or unexpected infection, unusual presentation, lack of seroconversion Infections in multiple recipients of a common donor is often the best (or only) clue
Slide 13-

WNV and TRANSPLANTATION Numerous case reports/series of TTWNV High mortality (~ 30%) Two instances of organ donor transmission of WNV (2003, 2005) Most common is community acquired WNV Immunocompetent : severe disease in 1:140
Slide 14-

ENCEPHALITIS Srinivasan et al. NEJM 2005 Rabies virus inclusions Four recipients of kidneys, liver, and of an illiac artery graft died of encephalitis of unknown cause. Onset within 21-27 days of surgery Donor presented 4 days prior (fever, mental status changes) Cocaine-induced subarachnoid hemorrhage In retrospect had a bat bite earlier
Slide 15-

YET ANOTHER UNUSUAL DONOR TRANSMITTED PATHOGEN Fischer et al. NEJM 2006 In 2003, 2005, 2-clusters of unusual infections 8 patients (2 donors): mental status changes, fever, rash, graft dysfunction, multi-organ failure (7/8 died 9-76 days) In 2005 cluster, donor had pet hamster IHC staining, RT-PCR, ELISA and culture: Lymphocytic Choriomeningitis (LCMV).
Slide 16-

Notable Organ Transplant-Transmitted Infections: Published Literature HIV, 1985 Hepatitis C, 2000 Chagas Disease (T. cruzi), 2001 West Nile Virus (WNV), GA 2002 Lymphocytic Choriomeningitis Virus (LCMV), WI 2003 and MA/RI 2005 Rabies, 2004 WNV, NY/PA 2005 Chagas, 2006 HIV/HCV 2007 Arenavirus 2007
Slide 17-

Aspects of Solid-Organ Transplantation That Should Be Disclosed during the Consent Process Known risks of transplantation include the rare risks of transmission of HIV, hepatitis B and C virus, and other infectious agents. Because of the scarcity of organs, organs from expanded-criteria donors, donors after circulatory determination of death, and donors with a slight risk of certain infections are sometimes used. Patients may decline nonstandard-criteria organs, but doing so may delay their receipt of an organ and possibly even result in death while they are on the waiting list.
Slide 18-

Aspects of Solid-Organ Transplantation That Should Be Disclosed during the Consent Process Physicians’ understanding of donor characteristics that confer risk is incomplete and continually evolving. New risks may arise in the future (e.g., as new transmittable infections are identified), and all efforts to minimize these risks will be made.
Slide 19-

CDC HIGH RISK BEHAVIOR Men who have had sex with another man in the preceding 5 years. Persons who report nonmedical intravenous, intramuscular, or subcutaneous injection of drugs in the preceding 5 years. Persons with hemophilia or related clotting disorders who have received human-derived clotting factor concentrates Men and women who have engaged in sex in exchange for money or drugs in the preceding 5 years. Persons who have had sex in the preceding 12 months with any person described above or with a person known or suspected to have HIV infection.
Slide 20-

CDC HIGH RISK BEHAVIOR Persons who have been exposed in the preceding 12 months to known or suspected HIV-infected blood through percutaneous inoculation or through contact with an open wound, nonintact skin, or mucous membrane. Inmates of correctional systems. (This exclusion is to address issues such as difficulties with informed consent and increased prevalence of HIV in this population.)
Slide 21-

Renal Transplants from CDC High-Risk Donors: What’s the Risk andfor Whom Is It Justified? METHODS: All high-risk donors underwent nucleic acid testing (NAT) for HIV, HCV, and HBV. Patients were counseled during evaluation and consent obtained rom all recipients highlighting the CDC high-risk status of the organ at the time of transplant. ATC 2010, ABSTRACT # 308
Slide 22-

Adult recipients were transplanted over the year beginning September, 2008. Given the increased risk, offers were directed towards older and diabetic patients, those with elevated PRA>50, and those already infected with HCV and/or HIV. All recipients had NAT at transplant and serially at 1, 3, and 6 months
Slide 23-

CONCLUSIONS: Although NAT reduces the window period between donor viral infection and detectability, the risk of transmission through transplant with these organs is ill-defined. Here, with prospective recipient NAT, we show safe use of high-risk kidneys with excellent short-term graft function. Risk of infection, however low, will clearly not be zero. With continued use of these organs and careful followup,we will be able to further gauge donor risk and match it to recipient need to optimize patient benefit.
Slide 24-

Donor Screening Epidemiologic history Serologic testing for VDRL, HIV,CMV, EBV, HSV, VZV, HBV (HBsAg, anti-HBsAg), and HCV Microbiologic testing of blood and urine Chest radiography Known infections (appropriate therapy?) Possible infections (e.g., encephalitis,sepsis) Special serologic testing, nucleic acid assays, or antigen detection based on epidemiologic factors and recent exposures (e.g., toxoplasma,West Nile virus, HIV, HCV
Slide 25-

Additional Donor Testing? NAT testing HIV - reduction in window period from 21 to 7 days HCV - reduction in window period - 70 to 7 days HBV West Nile Virus Other TB, Fungal, Chagas/T.cruzi, Strongyloides
Slide 26-

Recipient Screening Epidemiologic history Vaccination history, TB skin test Serologic testing for VDRL, HIV, CMV, EBV, HSV, VZV, HBV (HbsAg, anti-HbsAg), and HCV Microbiologic testing of blood and urine Chest radiography
Slide 27-

Recipient Screening Epidemiologic history Vaccination history, TB skin test Serologic testing for VDRL, HIV, CMV, EBV, HSV, VZV, HBV (HbsAg, anti-HbsAg), and HCV Microbiologic testing of blood and urine Chest radiography
Slide 28-

Recipient Screening Known infections (e.g., strongyloides, histoplasma, coccidioides, HBV or HCV viral load) Known infections Past colonization: prophylaxis? Active infection: appropriate therapy? Possible infections (e.g., encephalitis, sepsis) Special serologic testing, nucleic acid assays, or antigen detection based on epidemiologic factors and recent exposures
Slide 29-

Standard Assays Serologic tests for seroconversion Microbiologic cultures and susceptibility testing Quantitative viral-load assay and antigen tests Histopathological tests and immunostaining
Slide 30-

Advanced Assays Multiplex microbiologic assays Molecular antimicrobial-susceptibility testing Nonspecific immunoassays for degree of immunosuppression Intracellular ATP Biomarkers of rejection (cytokines) Proteomics
Slide 31-

Advanced Assays Assays of pathogen-specific immunity Cytotoxic lymphocytes Mixed lymphocyte cultures HLA-linked tetramers Intracellular cytokine staining Enzyme-linked immunospot assay Interferon-release assays
Slide 32-

Advanced Assays Genomics (patterns of gene expression) in: Immunosuppression Infection Rejection Drug metabolism
Slide 33-

Fishman JA. Infection in solid-organ transplant recipients. NEJM 2007; 357: 2601–2614.
Slide 34-

Tx ID TIMELINE: 0-1 MONTH Post-op Infections Technical / anastamotic related infection Nosocomial pneumonia, wound infection, UTI MRSA, VRE, Candida, C. difficile Donor Derived Infection These are rare but diagnosis can be missed Recipient derived infection Ongoing pneumonia Colonization to infection Most OI absent: exceptions include certain fungal infections, HSV, occasional others
Slide 35-

Tx ID TIMELINE 1-6 MONTH Account for CMV, PCP prophylaxis BK viruria / viremia, BKVAN CMV EBV viremia D+/R- HCV recurrence (OLTx) C. difficile, fungal, mycobacterial, respiratory virus VZV post-prophylaxis
Slide 36-

Tx ID TIMELINE >6 MONTH Depends on outcome: good vs. bad graft function. Tapering immunosuppression vs. ongoing high level – problems with rejection Some patients at ongoing risk of OI despite minimal exposures Others only get OI if significant exposure
Slide 37-

Tx ID TIMELINE >6 MONTH Late viral infections CMV (colitis, recurrence), BKVAN, PTLD, HCV Community acquired infection Respiratory virus, CA-MRSA, atypical mould infection, Other OI based on exposures
Slide 38-

FUNGAL INFECTIONS With improved strategies against CMV, fungal infection have become the most important cause of infectious mortality. Candida and Aspergillus account for ~ 80% of invasive fungal infections. Other 20% cryptococcus, other molds, and endemic mycosis.
Slide 39-

Incidence of Invasive fungal infection Renal 0-14% Heart 2-21% Liver 4-42% Lung 15-35% Intestinal 40-59% Pancreas 18-38%
Slide 40-

PREVENTION OF INFECTION PCP, UTI, others CMV disease Toxoplasmosis Other herpes viruses Candida Aspergillus Strongyloides Tuberculosis Endemic mycosis Bactrim Multiple strategies Bactrim, Pyrimethamine Acyclovir Azoles, echinocandins Voriconazole, candins, others Albendazole INH, ?others Voriconazole, others
Slide 41-

VACCINATIONS IN TRANSPLANT RECIPIENTS
Slide 42-

PRETRANSPLANT VACCINATION BOOSTERS TO BE GIVEN TO ALL TRANSPLANT RECIPIENTS UNLESS RECENT ADMINISTRATION CAN BE DOCUMENTED 1. Td (Tetanus toxoid, diphtheria) 2. Pneumococcal vaccine 3. Hepatitis B 4. Influenza
Slide 43-

PRETRANSPLANT VACCINATIONS TO BE GIVEN IF SERONEGATIVE OR PAST INFECTION BY HISTORY CANNOT BE DOCUMENTED 1. Measles-mumps-rubella vaccine 2. Polio 3. Varicella 4. Haemophilus influenza type B
Slide 44-

INACTIVATED VACCINES THAT ARE CONSIDERED SAFE AND MAY BE GIVEN AS NEEDED POST-TRANSPLANTFOR ANTICIPATED EXPOSURE 1. Anthrax 2. Cholera 3. Rabies vaccine absorbed 4. Human diploid cell rabies vaccine 5. Inactivated typhoid vaccine, capsular polysaccharide parenteral vaccine, or heat phenol-treated parenteral vaccine 6. Japanese encephalitis virus vaccine 7. Meningococcal vaccine 8. Plague vaccine
Slide 45-

VACCINES THAT MAY NOT BE GIVEN(LIVE ATTENUATED VACCINES) 1. Bacille Calmette-Guérin (BCG) 2. Measles 3. Mumps 4. Rubella 5. Oral polio 6. Oral typhoid 7. Yellow fever
Slide 46-

WHATS NEW? Changing immunosuppression Widespread prophylaxis Emerging infections Evolving infections Donor Derived infection Molecular diagnostics Host-pathogen interactions
Slide 47-

Clinical reactivation Subclinical reactivation
Slide 48-

Cytomegalovirus (CMV) Largest known virus to infect human beings greek cyto-, "cell", and -megalo-, "large”. In humans it is commonly known as HCMV or Human Herpesvirus 5 (HHV-5). belongs to the Betaherpesvirinae subfamily Other herpesviruses include Alphaherpesvirinae (HSV1/2 and VZV) Gammaherpesvirinae (including EBV).
Slide 49-

All herpesviruses share a characteristic ability to remain latent within the body over long periods. Nature Medicine, 6: 2000
Slide 50-

Prevalence of CMV In all geographic locations and S/E groups, infects between 50% and 80% of adults in the US  presence of antibodies (IgG) in much of the general population. Seroprevalence is age-dependent: 58.9% of individuals aged 6 & over-CMV+ & 90.8% of individuals aged 80 & over- CMV+.
Slide 51-

Spectrum of CMV In normal hosts: asymptomatic or causes an acute mono-like illness. Establishes latency in PMNs, T cells, endothelial cells, renal epithelium cells, and salivary gland. Wide spectrum of disease in immunocompromised hosts. One of the most important opportunistic pathogens, with more than 1 strain.
Slide 52-

Pathology CMV demonstrated by intranuclear inclusion bodies, showing the virus replicates in the nucleus rather than the cytosol. These inclusion bodies stain dark pink on an H&E stain, and are also called "Owl's Eye" inclusion bodies. Replicating virus disrupts the cytoskeleton, causing massive cell enlargement, which is the source of the virus' name.
Slide 53-

Definitions CMV infection Evidence of CMV replication regardless of symptoms CMV disease Evidence of CMV infection with attributable symptoms Viral syndrome with fever and/or malaise, leukopenia, thrombocytopenia, or tissue invasive disease
Slide 54-

Dynamics of Transplantation Immunosuppression Infection Rejection
Slide 55-

Impact of CMV on SOT DIRECT EFFECTS: Tissue Invasive Disease GI disease, Hepatitis Pneumonitis, Nephritis CNS disease, Retinitis Pancreatitis, Carditis Others Mortality INDIRECT EFFECTS: Acute allograft rejection Chronic allograft failure BOOP,vasculopathy, if/ta Vanishing duct syndrome OI: Fungal, Bacterial, PTLD, Hep.C recurrence, HHV-6, -7 NODAT
Slide 56-

Factors Influencing Reactivation of CMV and Progression to CMV Disease  CMV reactivation Allogeneic stimulation Allograft rejection Depleting antibodies Stress- critical illness, surgical procedure, bacterial & fungal sepsis progression to disease Lack of innate immunity (D+/R-) IS: depleting antibodies, MMF (> 2gm/day) High dose methylprednione Viral load
Slide 57-

Factors Influencing Reactivation of CMV and Progression to CMV Disease  CMV reactivation Allogeneic stimulation Allograft rejection Depleting antibodies Stress- critical illness, surgical procedure, bacterial & fungal sepsis progression to disease Lack of innate immunity (D+/R-) IS: depleting antibodies, MMF (> 2gm/day) High dose methylprednione Viral load
Slide 58-

Mechanisms of Acquiring CMV Infection After SOT Primary CMV infection (D+ /R-)- HIGH RISK (VIA TRANSPLANTED ORGAN OR TRANSUFION) Reactivation (D-/R+) -INTERMEDIATE RISK Superinfection (D+/R+) -INTERMEDIATE RISK Naïve (D-/R-) - LOW RISK (UNLESS TRANSFUSED D+ BLOOD PRODUCTS) Fishman JA et al. Clin Transplant 2007;21:149-158,
Slide 59-

Therapeutic Strategies for CMV UNIVERSAL PROPHYLAXIS: For the whole cohort, typically D+/R- (high risk) PRE-EMPTIVE THERAPY: For intermediate risk group (R+) vs Universal  2 weekly CMV-Pcr for 6 months, and initiate treatment doses of Valgancyclovir if positive STANDARD THERAPY: for patients with disease- treat with Vangancyclovir 900 mg bid until symptoms resolved, virologic clearance, or 2 week minimum. Then check Pcr & short course of prophylaxis (1-3 mo)
Slide 60-

CMV Prevention
Slide 61-

Recommendations Valganciclovir (Valcyte®) 900 mg valganciclovir daily = 5 mg/kg/day IV ganciclovir
Slide 62-

ESTIMATED INCIDENCE RATES OF CMV DISEASE AFTER KIDNEY AND/ OR PANCREAS TRANSPLANT CMV D+/ R- 45-65% with NO prophylaxis 6-29% with prophylaxis for 3 months CMV R+ 8-10% with NO prophylaxis 1-2% with prophylaxis for 3 months Eid AJ, Razonable R. Curr Opn Organ transplant, 2007:12;610-617
Slide 63-

ESTIMATED INCIDENCE RATES OF CMV DISEASE AFTER KIDNEY AND/ OR PANCREAS TRANSPLANT CMV D+/ R- 45-65% with NO prophylaxis 6-29% with prophylaxis for 3 months CMV R+ 8-10% with NO prophylaxis 1-2% with prophylaxis for 3 months Eid AJ, Razonable R. Curr Opn Organ transplant, 2007:12;610-617
Slide 64-

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR study Randomized, international trial, txp patients with CMV disease 900 mg po valganciclovir or 5 mg/kg IV ganciclovir BID for 21 days, followed by 900 mg daily valganciclovir for 28 days Rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI –14.0% to +8.0%), and at Day 49; 67.1% and 70.1% (p=NS) Treatment success was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS) Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs.19 days, p = 0.076) Asberg. Am J Transplant 2007; 7:2106-13.
Slide 65-

IMPACT study Multicentered, double-blind, RCT 326 high risk (D+/R-) kidney transplant patients randomized to 200 day vs 100 day valganciclvoir prophylaxis (900 mg daily) Inclusion criteria: ≥ 16 yo, D+/R-, CrCl > 10ml/min, tolerate oral study drug within 10 days of txp Exclusion criteria: HIV, HBV, HCV, suspected CMV disease at enrollment, anti-CMV therapy within 30 days prior to study, multiple organ txp, uncontrolled diarrhea or malabsorption, LFTs > 3xULN Humar Am J Transplant 2010;10:1228-37.
Slide 66-

IMPACT study Definitions CMV syndrome: CMV viremia, fever, malaise, leuokopenia, LFTs > 2 x ULN Tissue invasive CMV disease: evidence of localized CMV infection in biopsy or other specimen Primary endpoint: proportion of D+/R- patients who developed CMV disease within 1 year Secondary endpoint: CMV disease at 6 & 9 months, CMV viremia, and acute rejection .
Slide 67-

IMPACT study Results: CMV disease lower in 200 day vs 100 day (16.1% vs 36.8%, p <0.0001) Confirmed CMV viremia lower in 200 day vs 100 day (37.4% vs 50.9%, p=0.015) at month 12 Rejection in 200 day vs 100 day (11% vs 17%, p=0.114) Incidence of leukopenia 200 vs 100 day was 38% vs. 26% Humar Am J Transplant 2010;10:1228-37.
Slide 68-

IMPACT study Immunosuppressive regimens were not controlled HLA matching not analyzed Kidney transplant patients only Discontinuation of immunosuppression not assessed Humar Am J Transplant 2010;10:1228-37.
Slide 69-

CMV Resistance Risk factors Prolonged antiviral drug exposure Ongoing active viral replication Lack of prior CMV immunity Inadequate antiviral drug delivery Ganciclovir resistance incidence 5-10% 90% ganciclovir resistant CMV isolates contain UL97 mutations Less common UL54, pol mutation
Slide 70-

ppt slide no 70 content not found
Slide 71-

Foscarnet Treatment dose 90 mg/kg IV every 12 hours x 2 weeks Followed by 120 mg/kg daily for ≥ 2 weeks Infused over 1 hour Pre-treat with 500mls NSS over 1 hour prior to each dose, and repeat 500mls NSS over 1 hour after dose Adjust for renal dysfunction
Slide 72-

Our practice at UTHSC D+/R- : 900 mg valgancyclovir qd (renal adjusted dose) for 6 months R+ : 450 mg qd (renal adj) for 90 days OR po Valacyclovir (as below) + q 2wk CMV-PCR for 6 months- if PCR turns +VE, 900 mg bid for 2-4 wks, then ↓ to 900 mg qd D-/ R- : Valacyclovir 500 mg qd for 90 days
Slide 73-

BK Virus Nephropathy Kiran Babu, MD STAY TUNED !